Non-HDL cholesterol: Into the spotlight

Diabetes Care

Volumn 26, Issue 1, 2003, Pages 240-242

  Hsia, Stanley H ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; EDITORIAL; ETHNIC GROUP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MINORITY GROUP; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; RISK FACTORS;

EID: 0042170215     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.1.240     Document Type: Editorial

References (38)

1. Garg A, Grundy SM: Management of dyslipidemia in NIDDM. Diabetes Care 13:153-169, 1990
2. Assmann G, Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 70:733-737, 1992
3. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 (Suppl. 4A): 7B-12B, 1998
4. Sniderman AD, Silberberg J: Is it time to measure apolipoprotein B? Arterioscler 10:665-667, 1990
5. Marcovina SM, Albers JJ, Dati F, Ledue TB, Ritchie RF: International Federation of Clinical Chemistry standardization project for measurement of apolipoproteins A-I and B. Clin Chem 37:1676-1682, 1991
6. Keys A, Karvonen MJ, Punsar S, Menotti A, Fidanza F, Farchi G: HDL serum cholesterol and 24-year mortality of men in Finland. Intl J Epidemiol 13:428-435, 1984
7. Abate N, Vega GL, Grundy SM: Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atheroscler 104:159-171, 1993
8. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
9. Rubies-Prat J, Reverter JL, Senti M, Pedro-Botet J, Salinas I, Lucas A, Nogues X, Sanmarti A: Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 16:1081-1086, 1993
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2496, 2001
11. McNamara JR, Cole TG, Contois JH, Ferguson CA, Ordovas JM, Schaefer EJ: Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. Clin Chem 41:232-240, 1995
12. Pisani T, Gebski CP, Leary ET, Warnick GR, Ollington JF: Accurate direct determination of low-density lipoprotein cholesterol using an immunoseparation reagent and enzymatic cholesterol assay. Arch Pathol Lab Med 119:1127-1135, 1995
13. Whiting MJ, Shephard MDS, Tallis GA: Measurement of plasma LDL cholesterol in patients with diabetes. Diabetes Care 20:12-14, 1997
14. Havel RJ, Rapaport E: Management of primary hyperlipidemia. N Engl J Med 332:1491-1498, 1995
15. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care 26:16-23, 2003
16. Menotti A, Kromhout D, Nissinen A, Giampaoli S, Seccareccia F, Feskens E, Pekkanen J, Tervahauta M: Short-term all-cause mortality and its determinants in elderly male populations in Finland, the Netherlands, and Italy: the FINE Study. Prev Med 25:319-326, 1996
17. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359, 1997
18. Reed D, Benfante R: Lipid and lipoprotein predictors of coronary heart disease in elderly men in the Honolulu Heart Program. Ann Epidemiol 2:29-34, 1992
19. Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, Wilson PWF: Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 35:779-792, 1994
20. Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP, Isaacsohn JL, Wassertheil-Smoller S, Wilson AC, Stamler J, the Systolic Hypertension in the Elderly Research Group: Serum lipids and incidence of coronary heart disease: findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 94:2381-2388, 1996
21. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Int Med 161:1413-1419, 2001
22. Winkleby MA, Kraemer HC, Ahn DK, Varady AN: Ethnic and socioeconomic differences in cardiovascular disease risk factors: findings for women from the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA 280:356-362, 1998
23. Sundquist J, Winkelby MA: Cardiovascular risk factors in Mexican American adults: a transcultural analysis of NHANES III, 1988-1994. Am J Public Health 89:723-730, 1999
24. Gardner CD, Winkleby MA, Fortmann SP: Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1988-1994). Am J Cardiol 86:299-304, 2000
25. Elkeles RS, Diamond JR, El-Bahghouti N, Dhanjil S, Nicolaides A, Geroulakos G, Renton S, Anyaoku V, Richmond W, Mather H, Sharp P, the SENDCAP Study Group: Relative fasting hypoinsulinemia and ultrasonically measured early arterial disease in type 2 diabetes. Diabet Med 13:247-253, 1996
26. Hosoi M, Nishizawa Y, Kogawa K, Kawagishi T, Konishi T, Maekawa K, Emoto M, Fukumoto S, Shioi A, Shoji T, Inaba M, Okuno Y, Morii H: Angiotensin-converting enzyme gene polymorphism is associated with carotid arterial wall thickness in non-insulin-dependent diabetic patients. Circulation 94:704-707, 1996
27. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 21:1414-1431, 1998
28. Frost PH, Havel RJ: Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 81 (Suppl. 4A): 26B-31B, 1998
29. Grundy SM: Non-high-density lipoprotein cholesterol level as a potential risk predictor and therapy target. Arch Int Med 161:1379-1380, 2001
30. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA: Comparative effects of lovastatin and niacin in primary hypercholesterolemia. Arch Int Med 154:1586-1595, 1994
31. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C, the ACCESS Study Group: Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydorxymethylglutaryl coenzyme A reductase inhibitors on nonhigh-density lipoprotein cholesterol levels. Am J Cardiol 88:265-269, 2001
32. Aguilar-Salinas CA, Fanghanel-Salmon G, Meza E, Montes J, Gulias-Herrero A, Sanchez L, Monterrubio-Flores EA, Gonzalez-Valdez H, Gomez Perez FJ: Ciprofibrate versus gemfibrozil in the treatment of mixed dyslipidemias: an openlabel, multicenter study. Metab Clin Exp 50:1385-1386, 2001
33. Stein DT, Devaraj S, Balis D, Adams-Huet B, Jialal I: Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vase Biol 21:2026-2031, 2002
34. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J: Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 39:283-290, 2002
35. Dogra GK, Watts GF, Herrmann S, Thomas MA, Irish AB: Statin therapy improved brachial artery endothelial function in nephrotic syndrome. Kidney Int 62:550-557, 2002
36. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG: Treatment with atorvastatin to the National Cholesterol Education Program goal versus "usual" care in secondary coronary heart disease prevention: the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18:220-228, 2002
37. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pastemack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987
38. Cui Y, Blumenthal RS, Whiteman MK, Flaws JA: Prediction of cardiovascular mortality (Editorial Reply). Arch Int Med 162:109-110, 2002